AbbVie与Gubra合作开发肥胖药物GUB014295,预付350M美元。 AbbVie partners with Gubra to develop obesity drug GUB014295, with a $350M upfront payment.

AbbVie和Gubra已经签订了开发GUB014295的许可证协议,这是一个旨在治疗肥胖症的阿米林类比。 AbbVie and Gubra have entered a license agreement to develop GUB014295, an amylin analog aimed at treating obesity. GUB014295通过激活可减少食欲和食物摄入的受体来进行工作。 GUB014295 works by activating receptors that reduce appetite and food intake. AbbVie将领导发展和销售,而Gubra将提前收到3.5亿美元,达到18.75亿美元的里程碑和销售版税。 AbbVie will lead development and sales, while Gubra receives $350 million upfront, up to $1.875 billion in milestones, and sales royalties. 该药物正处于第一阶段试验阶段,目标是影响全球近9亿成年人的重大健康问题。 The drug is in a Phase 1 trial and targets a major health issue affecting nearly 900 million adults globally.